Isomorphic Laboratories Overview
Pro stress-test →Isomorphic Labs is an AI-driven drug discovery platform that uses computational tools to analyze biological phenomena and design molecules, predicting how therapeutic compounds perform to facilitate development of treatments for various diseases. The company is an AI-first drug design and development company backed by Alphabet and other major investors.
Strategic Profile
Pro stress-test →The company describes itself as an integrated drug design and development business built around its proprietary AI drug design engine, IsoDDE—not a licensable software platform but a unified drug design engine. Isomorphic Labs maintains strategic partnerships with industry leaders like Novartis, Lilly, and Johnson.
Competitive Landscape
Pro stress-test →Top competitors include Schrodinger, Recursion Pharmaceuticals, and XtalPi. The funding round signals AI drug discovery has entered a competitive phase, with large technology companies, pharmaceutical firms, and investors increasingly treating AI-enabled biology as a commercially important healthcare frontier.
Industry Context
Isomorphic Laboratories operates in AI-driven drug discovery platforms.
Key facts
Founded: 2021 · Headquarters: London, UK · Employees: 403 (as of June 2026) · Revenue: Private; estimated pre-revenue to early-stage revenue · Market cap: N/A